Abstract
Schizophrenia is one of the most disabling psychiatric conditions. Current treatments target monoamine receptors but this approach does not address the full complexity of the disorder. Here we explore the possibility of developing new anti-psychotics by targeting microRNAs (miRNAs), single stranded RNA molecules, 21 – 23 nucleotides in length that are not translated into proteins and regulate gene expression. The present review reveals that research involving schizophrenia and miRNA is very recent (the earliest report from 2007) and miRNAs add a significant layer of complexity to the pathophysiology of the disorder. However, miRNAs offer an exciting potential not only to understand the underlying mechanisms of schizophrenia, but also for the future development of antipsychotics, as the human miRNA system provides a rich and diverse opportunity for pharmacological targeting. However, technology is still developing in order to produce effective strategies to modulate specific and localized changes in miRNA, particularly in relation to the central nervous system and schizophrenia.
Keywords: Schizophrenia, miRNA, antipsychotics, non-coding nucleic acids
Current Pharmaceutical Design
Title: MicroRNAs: A Novel Therapeutic Target for Schizophrenia
Volume: 17 Issue: 2
Author(s): Javier A. Bravo and Timothy G. Dinan
Affiliation:
Keywords: Schizophrenia, miRNA, antipsychotics, non-coding nucleic acids
Abstract: Schizophrenia is one of the most disabling psychiatric conditions. Current treatments target monoamine receptors but this approach does not address the full complexity of the disorder. Here we explore the possibility of developing new anti-psychotics by targeting microRNAs (miRNAs), single stranded RNA molecules, 21 – 23 nucleotides in length that are not translated into proteins and regulate gene expression. The present review reveals that research involving schizophrenia and miRNA is very recent (the earliest report from 2007) and miRNAs add a significant layer of complexity to the pathophysiology of the disorder. However, miRNAs offer an exciting potential not only to understand the underlying mechanisms of schizophrenia, but also for the future development of antipsychotics, as the human miRNA system provides a rich and diverse opportunity for pharmacological targeting. However, technology is still developing in order to produce effective strategies to modulate specific and localized changes in miRNA, particularly in relation to the central nervous system and schizophrenia.
Export Options
About this article
Cite this article as:
A. Bravo Javier and G. Dinan Timothy, MicroRNAs: A Novel Therapeutic Target for Schizophrenia, Current Pharmaceutical Design 2011; 17 (2) . https://dx.doi.org/10.2174/138161211795049543
DOI https://dx.doi.org/10.2174/138161211795049543 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Propofol Pretreatment Prevents Oxygen-Glucose Deprivation/Reoxygenation (OGD/R)-induced Inflammation Through Nuclear Transcription Factor κB (NF-κB) Pathway in Neuroblastoma Cells
Current Neurovascular Research Current Review of Small Molecule Ret Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Lipid Modulation of Intravascular and Cellular Sodium Handling:Mechanistic Insights and Potential Clinical Implications
Current Vascular Pharmacology Increased CRMP2 Phosphorylation is Observed in Alzheimers Disease; Does this Tell us Anything About Disease Development?
Current Alzheimer Research Preliminary Study on Major Phenolic Groups, Antioxidant and Cytotoxic Capacity of Tuckeroo (<i>Cupaniopsis Anacardioides</i>) Fruit Extracts
Current Nutraceuticals Ubiquitylation and Cancer Development
Current Cancer Drug Targets Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal Dual-acting of Hybrid Compounds - A New Dawn in the Discovery of Multi-target Drugs: Lead Generation Approaches
Current Topics in Medicinal Chemistry Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews HDAC Inhibitors-New Generation of Target Specific Treatment
Mini-Reviews in Medicinal Chemistry Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer
Current Signal Transduction Therapy Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
Current Pharmaceutical Design The Use of DNA Microarrays to Investigate the Pharmacogenomics of Drug Response in Living Systems
Current Topics in Medicinal Chemistry Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry An Integrated Drug Development Approach Applying Topological Descriptors
Current Computer-Aided Drug Design Antimicrobial Photodynamic Therapy to Kill Gram-negative Bacteria
Recent Patents on Anti-Infective Drug Discovery Cyclotron Production of PET Radiometals in Liquid Targets: Aspects and Prospects
Current Radiopharmaceuticals HSP60 as a Drug Target
Current Pharmaceutical Design FAK and Nanog Cross Talk with p53 in Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Reposition of the Fungicide Ciclopirox for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery